.png){kind=small}
![[FDA breakthrough device designation] Shield ™ MCD](https://static.wixstatic.com/media/4c5620_aca234fe1ea144deab7569227a34e58f~mv2.png/v1/fill/w_1080,h_1080,al_c,q_90,enc_avif,quality_auto/4c5620_aca234fe1ea144deab7569227a34e58f~mv2.png)
[FDA breakthrough device designation] Shield ™ MCD
Guardant Health’s multi-cancer detection (MCD) test* is a blood-based test designed to detect 10 types of cancer, including bladder cancer, breast cancer, colorectal cancer, esophageal cancer, stomach cancer, liver cancer (hepatocellular carcinoma), lung cancer, pancreatic cancer, prostate cancer, and ovarian cancer.
Guardant Health’s multi-cancer detection (MCD) test* is a blood-based test designed to detect 10 types of cancer, including bladder cancer, breast cancer, colorectal cancer, esophageal cancer, stomach cancer, liver cancer (hepatocellular carcinoma), lung cancer, pancreatic cancer, prostate cancer, and ovarian cancer.
For individuals without symptoms, cancer screening can help detect cancer at an early stage. By the time symptoms appear, cancer is often already at a more advanced stage [1]. Early detection of cancer signs can improve survival rates and reduce mortality [1–3]. Overall, MCD testing has the potential to increase screening rates through a single blood test, thereby enhancing cancer detection capabilities [2].
Guardant Health’s multi-cancer detection (MCD) test* is not suitable for pregnant women or individuals who have previously been diagnosed with cancer. Your clinical eligibility will be determined by the medical professional with whom you have scheduled an appointment. There are no other restrictions for undergoing this test.
Guardant Health’s MCD test* is intended to complement routine cancer screening and does not replace standard, age-recommended cancer screening tests.
References:
[1] Madar, S.; Amor, R.E.; Furman-Assaf, S.; Friedman, E. Innovative Approaches to Early Detection of Cancer-Transforming Screening for Breast, Lung, and Hard-toScreen Cancers. Cancers 2025, 17, 1867. https://doi.org/10.3390/cancers17111867
[2] Carbonell C, Hutchinson JM, Hilsden RJ, Yang H, Brenner DR. Blood-Based MultiCancer Early Detection Tests (MCEDs) as a Potential Approach to Address Current Gaps in Cancer Screening. Cancer Control. 2024 Jan-Dec;31:10732748241307360. doi: 10.1177/10732748241307360
[3] Montena, J. (2024). Early cancer diagnosis: A crucial step toward better outcomes. Journal of Cancer Diagnosis, 2024(1), 1–5.
